Trial Profile
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of a Vaccine-based Immunotherapy Regimen-2 (VBIR-2) (PF-06936308) for Advanced Non-small Cell Lung Cancer and Metastatic Triple-negative Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs PF 06936308 (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 29 Apr 2022 Status changed from completed to discontinued.
- 02 Nov 2021 Status changed from recruiting to completed.
- 04 Oct 2021 Planned End Date changed from 24 Sep 2021 to 27 Sep 2021.